LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE

Boldizsár Jójárt  ¹     Noémi Csákány-Papp  ^{2, 3, 4}     Hajnalka Laub  ^{1, 2}     Béla Vasas  ²     Bence Barta  ⁵     Viktória Szabó  ^{2, 3, 4}     Mária Bagyánszki  ⁴     István Mándity  ^{1, 6}     Gábor Heltovics  ⁶     Petra Pallagi  ^{1, 2, 3, 7}     József Maléth  ^{1, 2, 3, 7    
1} Ladon Therapeutics Ltd, Szeged, Hungary
² University of Szeged, Szent-Györgyi Albert Medical School, Szeged, Hungary
³ ELKH-USz Momentum Epithelial Cell Signaling and Secretion Research Group, Szeged, Hungary
⁴ HCEMM-USz Molecular Gastroenterology Research Group, Szeged, Hungary
⁵ University of Szeged, Faculty of Science and Informatics, Szeged, Hungary
⁶ Research Centre for Natural Sciences, Institute of Materials and Environmental Chemistry, Budapest, Hungary
⁷ HCEMM-USz Molecular Gastroenterology Re

Topic
IBD

Session
Medical therapy of IBD: Facts and challenges (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)